Oversold

PHAR

Valuation25/ 100
Cash flow & growth33/ 100
Upside potential23/ 100
Risk potential52/ 100

PHAR's valuation is somewhat elevated, fundamentals are above averages and forward estimates point to earnings and revenue growth, though analyst coverage is limited and estimates vary widely.

Score change since last week

The score fell 9 points, mainly due to valuation and price changes. Price fell 4.0%, from $11.70 to $11.23.

Valuation and price changes subtracted 8.9 points. The comparison uses the same available inputs on both dates. Displayed changes are rounded to whole points.

Valuation

Historical cheapness: current PE is 87.7× versus the full-history median of 57.1× shown in the valuation table, producing 31.6/100. Positive weekly observations receive equal weight; lower past EPS alone does not disqualify them.

Outlook-adjusted valuation: 25/100. The model applies a -15.3% earnings-growth assumption and a 10% annual return hurdle, with positive credit limited by evidence coverage and confidence.

Forward price scenarios use recent PE history separately. Recent history has a separately weighted median of 84.8× (18-month half-life). The favorable scenario uses 86.5× PE and $0.1 projected EPS, informed by growth, margins and earnings-quality checks. This is a model scenario, not an analyst target. A return to the full-history median is not assumed.

Cash flow & growth

Business trends are weak. Over the past year: revenue -99.6%, operating margin -3.7 percentage points. Free cash flow is 8.6% of revenue. The business score is 32.5/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

The earnings calculation and the displayed scenario are different.

The earnings case uses $0.12 of EPS and a 86.5× PE, suggesting about $10.55 before the minimum is applied. Valuation history and outlook inform the PE.

The model applies a 15% minimum upside scenario, so the card shows +15%, or about $12.91. That adjusted price does not come from the EPS × PE calculation above.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

Weaker than expected earnings could put pressure on the share price.

Our downside case uses $0.08 of EPS and a 66.8× PE, suggesting a share price of about $5.43 — 52% below today’s price. Valuation history and outlook inform the PE.

This is a scenario based on our model, not a forecast or probability.

PHAR vs Historical averages

MetricCurrentAverageRelative
PE88x417x79% lower
PE percentile765053% higher
EPS$0.13$0.1112% higher
FCF$31.3M$21.7M44% higher
Loading historical comparisons…

PHAR’s earnings and cash flow are above their historical averages, while its earnings multiple is lower.

PHAR Forward outlook

MetricOutlook
Forward valuationStrongly improving
Forward earningsStrong growth
Forward revenueGrowth
Forward profitabilityStable
Analyst coverageLimited
Estimate dispersionWide

PHAR’s outlook is generally improving, though analyst coverage is limited.

PHAR PE Valuation

Loading pe valuation table…

This table applies PHAR's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

PHAR Earnings Per Share

Loading earnings per share…

This chart tracks PHAR's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

PHAR Quarterly Revenue

Loading quarterly revenue…

This chart tracks PHAR's quarterly revenue over time and shows how sales are changing from year to year.

PHAR Free Cash Flow

Loading free cash flow…

This chart tracks PHAR's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

PHAR Total Shares

Loading shares over time…

This chart tracks changes in PHAR's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

PHAR Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

PHAR PE vs Healthcare Sector

Loading pe vs sector average…

This chart compares PHAR's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

PHAR Weekly Price

Loading weekly price…

This chart uses PHAR's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

PHAR Weekly Moving Averages

Loading weekly moving averages…

This chart compares PHAR's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

PHAR Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.